{
    "nctId": "NCT00445406",
    "briefTitle": "Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer",
    "officialTitle": "Bevacizumab and Pegylated Liposomal Doxorubicin as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. A Multicenter, Single-Arm Phase II Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 43,
    "primaryOutcomeMeasure": "bevacizumab and doxorubicin hydrochloride liposome",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Cytologically or histologically confirmed breast cancer\n\n  * Metastatic OR locally recurrent disease\n  * Unresectable disease\n  * Not amenable to radiotherapy\n* Measurable disease, defined as \u2265 1 unidimensionally measurable lesion \u2265 20 mm by conventional techniques OR \u2265 10 mm by spiral CT scan\n\n  * Measurable disease must be outside irradiated areas\n* ErbB2-negative disease by immunohistochemistry (negative or 1+) or fluorescent in situ hybridization (FISH)\n* No known CNS metastases, even if previously treated\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Menopausal status not specified\n* WHO performance status 0-1\n* LVEF \u2265 55%\n* Hemoglobin \u2265 10.0 g/dL\n* Absolute neutrophil count \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Bilirubin \\< 2 times upper limit of normal (ULN)\n* ALT \u2264 2.5 times ULN (5 times ULN if liver metastases are present)\n* Alkaline phosphatase (AP) \u2264 2.5 times ULN\n\n  * AP \\> 2.5 times ULN and \u2264 6 times ULN allowed if ALT \u2264 1.5 times ULN\n  * AP \\> 6 times ULN allowed if ALT normal\n* Creatinine \u2264 1.5 times ULN\n* Proteinuria \\< 2+ by dipstick OR protein \u2264 1 g/24hr-urine collection\n* INR \u2264 1.5 OR Quick \u2265 70%\n* aPTT \u2264 1.5 times ULN\n* No peripheral neuropathy \\> grade 2\n* No history or evidence of hereditary bleeding diathesis or coagulopathy with the risk of bleeding\n* No uncontrolled hypertension, defined as systolic blood pressure (BP) \\> 150 mm Hg and/or diastolic BP \\> 100 mm Hg, measured repeatedly at \\> 2 visits despite adequate treatment with \u2265 2 different antihypertensive drugs\n* No clinically significant cardiovascular disease, including the following:\n\n  * Cerebrovascular accident or stroke within the past 6 months\n  * Myocardial infarction within the past 6 months\n  * Unstable angina\n  * New York Heart Association class II-IV congestive heart failure\n  * Serious cardiac arrhythmia (e.g., ventricular arrhythmia, high-grade atrioventricular-block) not controlled by medication or requiring medication which might interfere with regularity of the study treatment\n* No serious nonhealing wound, active peptic ulcer, nonhealing bone fracture, or bleeding skin metastases\n* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months\n* No active infection requiring IV antibiotics\n* No known hypersensitivity to any of the study drugs or excipients\n* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies\n* No evidence of any other disease that contraindicates the use of an investigational drug, that may affect patient compliance with study routines, or places the patient at high risk for treatment-related complications including, but not limited to, the following:\n\n  * Metabolic dysfunction\n  * Physical examination finding\n  * Psychological dysfunction\n  * Clinical laboratory finding giving reasonable suspicion of a disease or condition\n* No known CNS disease unrelated to cancer (e.g., uncontrolled seizures), unless adequately treated with standard medical therapy\n* No high-risk factors for bleeding, including the following:\n\n  * Coagulation parameters outside range\n  * Need for concurrent anticoagulant therapy\n  * Insufficient time gap after surgical procedures\n* No other malignancy within the past 5 years except for adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix\n* No significant traumatic injury within the past 28 days\n* No known HIV positivity\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 12 months after completion of study therapy\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior chemotherapy for metastatic or inoperable locally recurrent breast cancer\n* No prior bevacizumab or other anti-vascular endothelial growth factor drug therapy\n* No prior radiotherapy involving the heart (usual irradiation dose to breast or chest wall allowed)\n* More than 12 months since prior neoadjuvant or adjuvant chemotherapy\n* No neoadjuvant or adjuvant doxorubicin hydrochloride with cumulative dose \\> 360 mg/m\u00b2 or epirubicin hydrochloride with cumulative dose \\> 720 mg/m\u00b2\n* More than 6 months since prior adjuvant radiotherapy\n* More than 28 days since prior major surgical procedure with high risk of bleeding\n* More than 24 hours since prior minor surgical procedures\n* More than 10 days since prior acetylsalicylic acid (\\> 325 mg/day) or clopidogrel bisulfate (\\> 75 mg/day)\n* More than 10 days since prior and no concurrent use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes\n\n  * Prophylactic use of anticoagulants allowed (e.g., for maintenance of venous catheter)\n* More than 30 days since prior investigational therapies or participation in other investigational studies\n* No concurrent hormonal therapy\n* No other concurrent antineoplastic or antitumor therapy\n* No other concurrent investigational drugs\n* No concurrent radiotherapy\n* No concurrent nonsteroidal anti-inflammatory drugs with activity on platelets and gastric mucosa (e.g., dipyridamole, clopidogrel bisulfate, acetylsalicylic acid)\n* No anticipated need for major surgery during the course of the study treatment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}